Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VIPR1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VIPR1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View VIPR1 Products |
| Gene Delivery | VIPR1 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction to preserve GPCR native 7TM conformation. |
View VIPR1 Products |
| Benchmark Ab | Anti-VIPR1 Recombinant Antibody Recombinant positive control derived from public clinical sequences. |
View VIPR1 Products |
| Validator | VIPR1 siRNA Set For target knockdown verification in functional assays. |
View VIPR1 Products |
| Related Target A | VIPR2 Crucial subfamily homolog for selectivity counter-screening to avoid off-target vasodilation. |
View VIPR2 Products |
| Related Target B | VIP Natural ligand for competitive binding and receptor activation assays. |
View VIP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| 7-Transmembrane Conformation Loss | Lentivirus Premade Particles optimized for stable overexpression in cell-based functional assays (cAMP/Calcium flux) |
| Subfamily Cross-Reactivity (VIPR2) | Sequence-verified recombinant VIPR2 proteins available for precise counter-screening panels |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay validation and gating |
| False Positives | Validated siRNA sets included for target-specific knockdown verification |
Live VIPR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Vasoactive Intestinal Peptide Receptor 1 (VIPR1, also known as VPAC1) is expanding rapidly across immunology and oncology. As a Class B G-protein coupled receptor (GPCR), VIPR1 plays a dual role: its activation mediates anti-inflammatory pathways in autoimmune disorders, while its overexpression in solid tumors (such as breast, prostate, and lung cancers) makes it a prime candidate for targeted delivery and oncology therapeutics.
The race for VIPR1 therapeutics is intensifying, with major players shifting focus from traditional peptide agonists to monoclonal antibodies, small molecules, and antibody-drug conjugates (ADCs). As first-generation peptide therapeutics reach clinical evaluation, the next wave of R&D is targeting highly selective, non-peptide small molecules and biologics designed to avoid cross-activation of the closely related VIPR2 receptor, which is associated with systemic hypotension.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody / ADC | Biopharma Innovators | Solid Tumors (Breast, Colorectal) | Internalization Assay & Cell-surface Binding (Need Lentivirus for Stable Cell Lines) |
| Peptide / Small Molecule Agonist | Academic & Clinical Consortia | Rheumatoid Arthritis, Inflammatory Bowel Disease | cAMP Accumulation & Gs-Coupled Signaling (Need Lentivirus Premade Particles) |
| Targeted Radiopharmaceuticals | Oncology Research Institutes | Cancer Imaging & Targeted Therapy | High-affinity Binding & Selectivity Screening (Need Recombinant VIPR1 vs VIPR2 ECD) |